Leap Therapeutics, Inc.

NasdaqCM:LPTX Stock Report

Market Cap: US$111.5m

Leap Therapeutics Management

Management criteria checks 3/4

Leap Therapeutics' CEO is Doug Onsi, appointed in Jan 2011, has a tenure of 13.92 years. total yearly compensation is $1.53M, comprised of 43.6% salary and 56.4% bonuses, including company stock and options. directly owns 0.19% of the company’s shares, worth $214.31K. The average tenure of the management team and the board of directors is 4.7 years and 7.9 years respectively.

Key information

Doug Onsi

Chief executive officer

US$1.5m

Total compensation

CEO salary percentage43.6%
CEO tenure13.9yrs
CEO ownership0.2%
Management average tenure4.7yrs
Board average tenure7.9yrs

Recent management updates

Recent updates

Is Leap Therapeutics (NASDAQ:LPTX) In A Good Position To Deliver On Growth Plans?

Mar 13
Is Leap Therapeutics (NASDAQ:LPTX) In A Good Position To Deliver On Growth Plans?

Will Leap Therapeutics (NASDAQ:LPTX) Spend Its Cash Wisely?

Nov 22
Will Leap Therapeutics (NASDAQ:LPTX) Spend Its Cash Wisely?

Leap Therapeutics GAAP EPS of -$0.15 misses by $0.05

Aug 12

Leap Therapeutics begins trials of DKN-01 in gastric/colorectal cancers

Jul 12

Leap Therapeutics: 2 Catalysts With Cancer Drug DKN-01 In The 2nd Half Of 2022

Jun 27

Here's Why We're Watching Leap Therapeutics' (NASDAQ:LPTX) Cash Burn Situation

May 01
Here's Why We're Watching Leap Therapeutics' (NASDAQ:LPTX) Cash Burn Situation

Leap Therapeutics: Waiting For One More Leap

Feb 18

We're Hopeful That Leap Therapeutics (NASDAQ:LPTX) Will Use Its Cash Wisely

Jan 04
We're Hopeful That Leap Therapeutics (NASDAQ:LPTX) Will Use Its Cash Wisely

Leap Therapeutics: What Prompted Prioritizing This Precision Oncology Company?

Nov 29

Leap Therapeutics: All On The Line

Oct 13

Is Leap Therapeutics (NASDAQ:LPTX) In A Good Position To Invest In Growth?

Sep 15
Is Leap Therapeutics (NASDAQ:LPTX) In A Good Position To Invest In Growth?

Is Leap Therapeutics (NASDAQ:LPTX) In A Good Position To Invest In Growth?

Jun 01
Is Leap Therapeutics (NASDAQ:LPTX) In A Good Position To Invest In Growth?

Companies Like Leap Therapeutics (NASDAQ:LPTX) Are In A Position To Invest In Growth

Mar 03
Companies Like Leap Therapeutics (NASDAQ:LPTX) Are In A Position To Invest In Growth

Could The Leap Therapeutics, Inc. (NASDAQ:LPTX) Ownership Structure Tell Us Something Useful?

Jan 27
Could The Leap Therapeutics, Inc. (NASDAQ:LPTX) Ownership Structure Tell Us Something Useful?

Announcing: Leap Therapeutics (NASDAQ:LPTX) Stock Increased An Energizing 127% In The Last Year

Dec 23
Announcing: Leap Therapeutics (NASDAQ:LPTX) Stock Increased An Energizing 127% In The Last Year

Need To Know: Analysts Are Much More Bullish On Leap Therapeutics, Inc. (NASDAQ:LPTX)

Nov 18
Need To Know: Analysts Are Much More Bullish On Leap Therapeutics, Inc. (NASDAQ:LPTX)

CEO Compensation Analysis

How has Doug Onsi's remuneration changed compared to Leap Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$65m

Jun 30 2024n/an/a

-US$60m

Mar 31 2024n/an/a

-US$53m

Dec 31 2023US$2mUS$669k

-US$81m

Sep 30 2023n/an/a

-US$81m

Jun 30 2023n/an/a

-US$82m

Mar 31 2023n/an/a

-US$86m

Dec 31 2022US$2mUS$637k

-US$55m

Sep 30 2022n/an/a

-US$53m

Jun 30 2022n/an/a

-US$49m

Mar 31 2022n/an/a

-US$42m

Dec 31 2021US$2mUS$596k

-US$41m

Sep 30 2021n/an/a

-US$37m

Jun 30 2021n/an/a

-US$32m

Mar 31 2021n/an/a

-US$29m

Dec 31 2020US$2mUS$513k

-US$38m

Sep 30 2020n/an/a

-US$39m

Jun 30 2020n/an/a

-US$40m

Mar 31 2020n/an/a

-US$42m

Dec 31 2019US$817kUS$400k

-US$33m

Sep 30 2019n/an/a

-US$24m

Jun 30 2019n/an/a

-US$22m

Mar 31 2019n/an/a

-US$21m

Dec 31 2018US$682kUS$400k

-US$23m

Sep 30 2018n/an/a

-US$31m

Jun 30 2018n/an/a

-US$31m

Mar 31 2018n/an/a

-US$31m

Dec 31 2017US$3mUS$397k

-US$30m

Compensation vs Market: Doug's total compensation ($USD1.53M) is above average for companies of similar size in the US market ($USD653.16K).

Compensation vs Earnings: Doug's compensation has been consistent with company performance over the past year.

CEO

Doug Onsi (55 yo)

13.9yrs

Tenure

US$1,534,507

Compensation

Mr. Douglas E. Onsi, also known as Doug, J.D., serves as Director at Leap Therapeutics, Inc. since March 18, 2020. He serves as Managing Director of HCV Management VIII, LLC (formerly known as HealthCare V...

Leadership Team

NamePositionTenureCompensationOwnership
Douglas Onsi
CFO, General Counsel13.9yrsUS$1.53m0.19%
$ 214.3k
Augustine Lawlor
Chief Operating Officer8.9yrsUS$1.00m0.013%
$ 14.8k
Cynthia Sirard
Chief Medical Officer4.7yrsUS$999.40k0.013%
$ 14.6k
Jason Baum
Chief Scientific Officer1.7yrsno datano data
Mark O'Mahony
Chief Manufacturing Officer4.7yrsno data0.013%
$ 14.6k
Christine Granfield
VP and Head of Regulatory Affairs & Quality4.3yrsno datano data

4.7yrs

Average Tenure

54.5yo

Average Age

Experienced Management: LPTX's management team is considered experienced (4.7 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Douglas Onsi
CFO, General Counsel4.8yrsUS$1.53m0.19%
$ 214.3k
Christopher Mirabelli
Chairman13.9yrsUS$744.18k0.013%
$ 14.8k
James Cavanaugh
Independent Director8.9yrsUS$126.62k0.68%
$ 762.6k
Thomas Dietz
Lead Independent Director8.9yrsUS$188.86k0%
$ 0
Nissim Mashiach
Independent Director7.9yrsUS$118.24k0%
$ 0
Joseph Loscalzo
Independent Director8.9yrsUS$112.12k0%
$ 0
William Li
Independent Director7.9yrsUS$121.62k0%
$ 0
Carl Nathan
Member of Scientific Advisory Boardno datano datano data
Richard Schilsky
Independent Director2.3yrsUS$112.12k0%
$ 0
Richard Brian Gaynor
Member of Scientific Advisory Board3.9yrsno datano data
David Tuveson
Member of Scientific Advisory Boardno datano datano data
Andrew Nixon
Member of Scientific Advisory Board3.9yrsno datano data

7.9yrs

Average Tenure

70yo

Average Age

Experienced Board: LPTX's board of directors are considered experienced (7.9 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 02:17
End of Day Share Price 2024/12/23 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Leap Therapeutics, Inc. is covered by 8 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Madhu KumarBaird
Joel BeattyBaird
Swayampakula RamakanthH.C. Wainwright & Co.